vs
KINGSTONE COMPANIES, INC.（KINS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
KINGSTONE COMPANIES, INC.的季度营收约是REGENXBIO Inc.的1.9倍（$56.4M vs $30.3M），KINGSTONE COMPANIES, INC.净利率更高（26.2% vs -221.3%，领先247.5%），REGENXBIO Inc.同比增速更快（43.0% vs 34.0%），KINGSTONE COMPANIES, INC.自由现金流更多（$73.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 25.6%）
金斯顿公司总部位于纽约金斯顿，核心业务通过旗下金斯顿保险公司开展财产意外保险产品服务，同时旗下持纽约州牌照的保险保费融资公司Payments, Inc.，会与第三方持牌保费融资机构签订合作协议。在2010年专业保险代理人协会的企业绩效调查中，金斯顿保险公司在81家参评保险公司中排名第一。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
KINS vs RGNX — 直观对比
营收规模更大
KINS
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出9.0%
34.0%
净利率更高
KINS
高出247.5%
-221.3%
自由现金流更多
KINS
多$125.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
25.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.4M | $30.3M |
| 净利润 | $14.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 32.7% | -190.0% |
| 净利率 | 26.2% | -221.3% |
| 营收同比 | 34.0% | 43.0% |
| 净利润同比 | 171.4% | -31.2% |
| 每股收益（稀释后） | $1.09 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KINSRGNX
| Q4 25 | $56.4M | $30.3M | ||
| Q3 25 | $55.7M | $29.7M | ||
| Q2 25 | $52.3M | $21.4M | ||
| Q1 25 | $50.5M | $89.0M | ||
| Q4 24 | $42.1M | $21.2M | ||
| Q3 24 | $40.8M | $24.2M | ||
| Q2 24 | $36.5M | $22.3M | ||
| Q1 24 | $35.8M | $15.6M |
净利润KINSRGNX
| Q4 25 | $14.8M | $-67.1M | ||
| Q3 25 | $10.9M | $-61.9M | ||
| Q2 25 | $11.3M | $-70.9M | ||
| Q1 25 | $3.9M | $6.1M | ||
| Q4 24 | $5.4M | $-51.2M | ||
| Q3 24 | $7.0M | $-59.6M | ||
| Q2 24 | $4.5M | $-53.0M | ||
| Q1 24 | $1.4M | $-63.3M |
毛利率KINSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率KINSRGNX
| Q4 25 | 32.7% | -190.0% | ||
| Q3 25 | 24.6% | -176.3% | ||
| Q2 25 | 27.1% | -296.3% | ||
| Q1 25 | 9.3% | 13.6% | ||
| Q4 24 | 15.9% | -242.1% | ||
| Q3 24 | 22.3% | -256.6% | ||
| Q2 24 | 15.7% | -251.3% | ||
| Q1 24 | 5.0% | -408.8% |
净利率KINSRGNX
| Q4 25 | 26.2% | -221.3% | ||
| Q3 25 | 19.5% | -208.3% | ||
| Q2 25 | 21.5% | -331.8% | ||
| Q1 25 | 7.7% | 6.8% | ||
| Q4 24 | 12.9% | -241.3% | ||
| Q3 24 | 17.1% | -246.3% | ||
| Q2 24 | 12.4% | -237.7% | ||
| Q1 24 | 4.0% | -405.4% |
每股收益（稀释后）KINSRGNX
| Q4 25 | $1.09 | $-1.30 | ||
| Q3 25 | $0.74 | $-1.20 | ||
| Q2 25 | $0.78 | $-1.38 | ||
| Q1 25 | $0.27 | $0.12 | ||
| Q4 24 | $0.44 | $-0.99 | ||
| Q3 24 | $0.55 | $-1.17 | ||
| Q2 24 | $0.37 | $-1.05 | ||
| Q1 24 | $0.12 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $4.4M | — |
| 股东权益账面价值 | $122.7M | $102.7M |
| 总资产 | $453.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.04× | — |
8季度趋势，按日历期对齐
现金及短期投资KINSRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务KINSRGNX
| Q4 25 | $4.4M | — | ||
| Q3 25 | $4.8M | — | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $11.2M | — | ||
| Q3 24 | $17.3M | — | ||
| Q2 24 | $25.3M | — | ||
| Q1 24 | $25.3M | — |
股东权益KINSRGNX
| Q4 25 | $122.7M | $102.7M | ||
| Q3 25 | $107.7M | $161.5M | ||
| Q2 25 | $94.9M | $213.7M | ||
| Q1 25 | $82.2M | $274.2M | ||
| Q4 24 | $66.7M | $259.7M | ||
| Q3 24 | $59.7M | $301.4M | ||
| Q2 24 | $40.8M | $348.3M | ||
| Q1 24 | $35.7M | $390.7M |
总资产KINSRGNX
| Q4 25 | $453.4M | $453.0M | ||
| Q3 25 | $428.6M | $525.2M | ||
| Q2 25 | $393.4M | $581.0M | ||
| Q1 25 | $385.4M | $490.9M | ||
| Q4 24 | $374.9M | $466.0M | ||
| Q3 24 | $347.0M | $519.1M | ||
| Q2 24 | $319.8M | $569.4M | ||
| Q1 24 | $318.3M | $629.2M |
负债/权益比KINSRGNX
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.17× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $73.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 129.5% | -174.0% |
| 资本支出强度资本支出/营收 | 5.0% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.14× | — |
| 过去12个月自由现金流最近4个季度 | $124.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流KINSRGNX
| Q4 25 | $75.9M | $-52.3M | ||
| Q3 25 | $25.9M | $-56.0M | ||
| Q2 25 | $9.3M | $-49.3M | ||
| Q1 25 | $17.9M | $33.6M | ||
| Q4 24 | $57.9M | $-31.6M | ||
| Q3 24 | $21.7M | $-40.5M | ||
| Q2 24 | $7.1M | $-45.5M | ||
| Q1 24 | $6.1M | $-55.5M |
自由现金流KINSRGNX
| Q4 25 | $73.1M | $-52.8M | ||
| Q3 25 | $25.3M | $-56.5M | ||
| Q2 25 | $8.7M | $-49.7M | ||
| Q1 25 | $17.0M | $32.6M | ||
| Q4 24 | $55.6M | $-32.7M | ||
| Q3 24 | $21.0M | $-40.9M | ||
| Q2 24 | $6.6M | $-46.0M | ||
| Q1 24 | $5.6M | $-56.0M |
自由现金流率KINSRGNX
| Q4 25 | 129.5% | -174.0% | ||
| Q3 25 | 45.4% | -189.9% | ||
| Q2 25 | 16.6% | -232.8% | ||
| Q1 25 | 33.7% | 36.6% | ||
| Q4 24 | 132.1% | -154.2% | ||
| Q3 24 | 51.6% | -168.9% | ||
| Q2 24 | 18.1% | -206.2% | ||
| Q1 24 | 15.5% | -358.5% |
资本支出强度KINSRGNX
| Q4 25 | 5.0% | 1.7% | ||
| Q3 25 | 1.2% | 1.7% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 5.6% | 5.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 1.4% | 2.1% | ||
| Q1 24 | 1.5% | 3.6% |
现金转化率KINSRGNX
| Q4 25 | 5.14× | — | ||
| Q3 25 | 2.38× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 4.60× | 5.53× | ||
| Q4 24 | 10.65× | — | ||
| Q3 24 | 3.12× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 4.27× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KINS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
